MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor

Archives of Gynecology and Obstetrics

Volumn 287, Issue 3, 2013, Pages 563-570

  Halon, Agnieszka ^a   Materna, Verena ^b   Donizy, Piotr ^a   Matkowski, Rafal ^a,c   Rabczynski, Jerzy ^a   Lage, Hermann ^b   Surowiak, Pawel ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Charité Campus Benjamin Franklin Medical Center   (Germany)

^c Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

Author keywords

Cisplatin resistance; Immunohistochemistry; MRP2; Primary fallopian tube carcinoma; Prognostic factor

Indexed keywords

CISPLATIN; MULTIDRUG RESISTANCE PROTEIN 2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL TIME; UTERINE TUBE CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA; CARCINOMA, ENDOMETRIOID; CARCINOMA, TRANSITIONAL CELL; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NUCLEAR ENVELOPE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84878371468     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2589-7     Document Type: Article

References (45)

1. Reports based on data of the National Cancer Registry in Poland: http://85.128.14.124/krn/english/index.asp
2. Stewart SL, Wike JM, Foster SL, Michaud F (2007) The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 107:392-397
3. Wethington SL, Herzog TJ, Seshan VE et al (2008) Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 113:3298-3306
4. Hu CY, Taymour ML, Hertig AT (1950) Primary carcinoma of the fallopian tube. Am J Obstet Gynaecol 59:58-67
5. Sedlis A (1978) Carcinoma of the fallopian tube. Surg Clin North Am 58:121-129
6. Ng P, Lawton F (1998) Fallopian tube carcinoma-a review. Ann Acad Med Singapore 27:693-697
7. Karst AM, Levanon K, Drapkin R (2011) Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 108:7547-7552
8. Levanon K, Crum C, Drapkin R (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26:5284-5293
9. Alvarado-Cabrero I, Young RH, Vamvakas EC et al (1999) Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 72:367-379
10. Baekelandt M, Nesbakken AJ, Kristensen GB et al (2000) Carcinoma of the fallopian tube. Clinicopathologic study of 151 patients treated at the Norwegian Radium Hospital. Cancer 89:2076-2084
11. Nordin AJ (1994) Primary carcinoma of the fallopian tube: a 20-year literature review. Obstet Gynaecol Surv 49:349-361
12. Hellström AC, Silfverswärd C, Nilsson B et al (1994) Carcinoma of the fallopian tube. A clinical and histopathologic review. The Radiumhemmet series. Int J Gynecol Cancer 4:395-400
13. Rosen AC, Ausch M, Hafner E et al (1998) A 15-year overview of management and prognosis in fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Eur J Cancer 34:1725-1729
14. Rabczyński J, Ziółkowski P, Kochman A et al (1998) Primary fallopian tube carcinoma. Histopathology of 46 cases. Pol J Pathol 49:285-292
15. Papadimitriou CA, Markaki S, Lianos E et al (2009) Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. Eur J Gynaecol Oncol 30:389-395
16. Pectasides D, Pectasides E, Papaxoinis G et al (2009) Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol 115:97-101
17. Liapis A, Bakalianou K, Mpotsa E et al (2008) Fallopian tube malignancies: a retrospective clinical pathological study of 17 cases. J Obstet Gynaecol 28:93-95
18. Rose PG, Shrigley R, Wiesner GL (2000) Germline BRCA2 mutation in patient with primary fallopian tube carcinoma: a case report. Gynecol Oncol 77:319-320
19. Aziz S, Kuperstein G, Rosen B et al (2001) A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 80:341-345
20. Pectasides D, Pectasides E, Economopoulos T (2006) Fallopian tube carcinoma: a review. Oncologist 11:902-912
21. Kosary C, Trimble EL (2002) Treatment and survival for women with fallopian tube carcinoma: a population-based study. Gynecol Oncol 86:190-191
22. Gadducci A, Landoni F, Sartori E et al (2001) Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol 81:150-159
23. Peters WA, Andersen WA, Hopkins MP (1988) Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol 71:757-762
24. Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537-7552
25. Taniguchi K, Wada M, Kohno K et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124-4129
26. Liedert B, Materna V, Schadendorf D et al (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121:172-176
27. Surowiak P, Materna V, Kaplenko I et al (2006) ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 12:7149-7158
28. Wada M, Toh S, Taniguchi K et al (1998) Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 7:203-207
29. Materna V, Stege A, Surowiak P et al (2006) RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun 348:153-157
30. Kowalski P, Surowiak P, Lage H (2005) Reversal of drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther 11:1393-1398
31. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138-140
32. Yamasaki M, Makino T, Masuzawa T et al (2011) Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104:707-713
33. Ruggeri RM, Sciacchitano S, Vitarelli E et al (2006) Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas. Arch Pathol Lab Med 130:1014-1019
34. Noma B, Sasaki T, Fujimoto Y et al (2008) Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 33:1187-1194
35. van den Broek GB, Wildeman M, Rasch CR et al (2009) Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124:2643-2650
36. Kim YH, Ishii G, Goto K et al (2009) Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:105-111
37. Ushijima R, Takayama K, Izumi M et al (2007) Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 27:4351-4358
38. Korita PV, Wakai T, Shirai Y et al (2010) Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 23:965-972
39. Rau S, Autschbach F, Riedel HD et al (2008) Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. Eur J Clin Invest 38:134-142
40. Sandusky GE, Mintze KS, Pratt SE et al (2002) Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41:65-74
41. Chen H, Hao J, Wang L (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDRI, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101:432-440
42. Ohishi Y, Oda Y, Uchiumi T et al (2002) ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8:3767-3775
43. Materna V, Pleger J, Hoffmann U et al (2004) RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94:152-160
44. Guminski AD, Balleine RL, Chiew YE et al (2006) MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol 100:239-246
45. Ma JJ, Chen BL, Xin XY (2009) Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279:149-157